Advertisement

Volume 2, Issue 1

 

Cover Image

Cover Figure: Homology models of the proton-coupled folate transporter in the inward-open (blue) and outward-open (green) conformations. See the article by Aluri et al.

WASHINGTON, January 9,  2018 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Germ line mutations in the regulator of telomere elongation helicase 1 (RTEL1) have been associated with short telomeres and dyskeratosis congenita. The role of RTEL1 in hematological diseases including bone marrow failure states has been controversial. Mufti and colleagues screened a large number of patients, many of whom had bone marrow dysfunction for RTEL1 mutations. Their findings help elucidate the role of this gene in these diverse disorders.

Clonal heterogeneity is a hallmark of many cancers, including hematologic malignancies. In the study by Merz and colleagues plasma cell samples from newly diagnosed patients with multiple myeloma enrolled in the HOVON-65/GMMG-HD4 phase 3 trial were analyzed by interphase fluorescence in situ hybridization to identify subclonal cytogenetic abnormalities. These abnormalities were commonly found and had significant clinical implications, which the authors discuss.

 


Featured Visual Abstract

Glycophorin-C sialylation regulates Lu/BCAM adhesive capacity during erythrocyte aging

T. R. L. Klei, D. Z. de Back, P. J. Asif, P. J. J. H. Verkuijlen, M.Veldthuis, P. C. Ligthart, J. Berghuis, E. Clifford, B. M. Beuger, T. K.van den Berg, R. van Zwieten, W. El Nemer and R. van Bruggen

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.